Genomic DNA of autologous CD34+ hematopoietic stem cells (CD34+ HSC genomic DNA)

The genomic DNA of autologous CD34+ hematopoietic stem cells (HSCs) represents the fundamental genetic blueprint of a patient's own blood-forming progenitor cells. These cells are characterized by the expression of the CD34 surface marker and possess the unique ability to self-renew and differentiate into all mature blood cell types, including erythrocytes, leukocytes, and platelets (StatPearls, 2023). In the context of regenerative medicine and gene therapy, this genomic DNA is the primary target for ex vivo modifications designed to correct underlying genetic defects. Therapeutic strategies involve harvesting these cells from the patient and using technologies such as lentiviral vectors for gene addition or CRISPR/Cas9 for precise gene editing to alter the genomic sequence (N Engl J Med, 2021). Once modified, the cells are re-infused into the patient, where they engraft in the bone marrow to provide a long-term, potentially curative source of functional blood cells. This target is central to the treatment of disorders like sickle cell disease, beta-thalassemia, and certain primary immunodeficiencies (FDA, 2023).

Other names

Autologous CD34+ cellsHematopoietic stem cell genomeHSC genomic DNAPatient-derived CD34+ progenitor cell DNA

Ex vivo genetic modification of hematopoietic stem cells via viral vector-mediated gene addition or CRISPR-Cas9-mediated gene editing to restore or alter protein expression.